Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bristol-Myers Squibb Company BOERSE MUENCHEN

Equities

BRM

US1101221083

Real-time BOERSE MUENCHEN
Other stock markets
 12:13:51 27/06/2024 am IST 		5-day change 1st Jan Change
39.82 EUR +1.08% Intraday chart for Bristol-Myers Squibb Company +3.66% -15.27%
06:28pm Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
05:27pm Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer
CI
US FDA approves Bristol Myers' colorectal cancer therapy
RE
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo
CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5
MT
Bristol Myers: Board declares dividend
CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024
CI
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors
MT
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb
MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb
MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
CI
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial
MT
Geron shares surge after U.S. FDA approves blood disorder drug
RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers
MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. News Bristol-Myers Squibb Company
  6. Highlights